Business
CNS Pharmaceuticals Continues to Execute on Corporate, Clinical and Regulatory Strategies to Drive Berubicin Towards Commercialization for the Treatment of GBM
Recently launched potentially pivotal study for lead program evaluating Berubicin in the treatment of adult Glioblastoma Multiforme (GBM), with patient dosing
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Recently launched potentially pivotal study for lead program evaluating Berubicin in the treatment of adult Glioblastoma Multiforme (GBM), with patient dosing expected to commence in Q3 2021\n Continued execution on clinical and regulatory strategies to advance development of Berubicin\n Company strengthens balance sheet with ~$4.7 million from ATM at average price of $2.32\n\n\nHOUSTON, July 1, 2021 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today provided a business update.\n\n \n \n \n \n \n \n\n \nRecent Highlights\nSecured an additional $4.7 million in gross proceeds from ATM at average price of $2.32; extending the Company's cash runway to Q2 2022; Granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for lead investigational drug candidate, Berubicin, for the treatment of patients with recurrent GBM; and Commenced enrollment in potentially pivotal study evaluating the efficacy and safety of Berubicin in the treatment of recurrent GBM.\"In the last 60 days alone we have achieved fundamental clinical, regulatory and corporate milestones that together demonstrate CNS' operational, strategic and financial strengths. We are continuously de-risking our Berubicin clinical program by driving development of this truly novel treatment forward as expeditiously as possible. In a mere 18 months from our IPO our laser focus on this program created a potentially pivotal study now open for enrollment with patient dosing expected to commence at any time. With the addition of our recent Fast Track Designation for GBM, we believe we are poised to execute on our milestones ahead and bring a meaningful treatment to patients who suffer from this devasting and heretofore incurable disease,\" commented John Climaco, CEO of CNS Pharmaceuticals. \"Additionally, the $4.7 million of ATM transactions significantly bolsters our cash runway and provides funding to advance our important clinical programs for several quarters to come. We are passionate about driving Berubicin's development forward, creating value in the near- and long-term, and most importantly making a positive impact on patients lives.\"\nClinical Programs Update ...